Dr Sonia Yip

Oncology Translational Research Fellow
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 9562 5345
Fax +61 2 9562 5094

Map

Biographical details

Sonia Yip is the Oncology Translational Research Fellow and Manager at the NHMRC Clinical Trials Centre, Sydney Medical School. She works with 5 national oncology co-operative trials groups designing, developing and implementing biological/ranslational studies as part of investigator-initiated clinical trials.

Sonia is also Senior Translational Research Fellow of Sydney Catalyst Translational Cancer ResearchCentre, working in Bench to Bedside translational research (T1-2).

Selected grants

2016

  • Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 Trial); Shannon J, Goldstein D, Merrett N, Maddern G, Sjoquist K, Samra J, Tebbutt N, Yip S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • B-PPAE - Biobanking-patient & healthcare professional attitudes & experiences; Yip S; University of Sydney - Sydney Catalyst Translational Cancer Research/Research Grant.
  • VERTU - VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma; Khasraw M, Simes R, Rosenthal M, McDonald K, Koh E, Ashley D, Buckland M, Barnes E, Goh C, Yip S; Cancer Council New South Wales/Priority-driven Collaborative Cancer Research Scheme.

2015

  • LC-PLAT - Lung Cancer Cohort - A Platform to Study Serial Biospecimens And Matched Clinical Data; Yip S; University of Sydney/Sydney Catalyst.

2014

  • The Sydney Cancer Conference 2014 Bridging Research and Practice - Ian Potter Foundation Conference grant; Yip S, Reid G; Ian Potter Foundation/Travel Support.
  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Shannon C, Martyn J, Yip S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2013

  • Biobanking Stakeholder Network (BSN) Pre-Operative Consent Project; Yip S, Hawkins N, Miller D, Horvath L, Kench J, Brown S; Cancer Institute New South Wales/Community of Practice.
  • Technical services of a genomic cancer clinical trial initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols; Stockler M, Simes R, Vachan B, Sjoquist K, Lee C, Yip S, Evans A; Cancer Australia/Request for Tender.
  • The biological basis of success or failure to the anti-VEGF agent, bevacizumab in patients with recurrent glioblastoma; Simes R, McDonald K, Brown C, Yip S; Cancer Council New South Wales/Research Project Grants.

2012

  • Personalising care in resectable pancreas cancer. GAP-T: a study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery.; Barbour A, Goldstein D, Goldstein D, Kench J, Yip S, Mead S, Brown C, Chang D; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • DOCetaxel with or without radiation Therapy for resectable Oesophageal adenocarcinoma based on early PET Response to induction chemotherapy (DOCTOR); Goldstein D, Brown C, Yip S, Barbour A; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Pavlakis, N., Sjoquist, K., Martin, A., Tsobanis, E., Yip, S., Kang, Y., Bang, Y., Alcindor, T., O'Callaghan, C., Burnell, M., Wong, K., Simes, R., et al (2016). Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial. Journal of Clinical Oncology, 34(23), 2728-2735. [More Information]
  • Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
  • Chantrill, L., Nagrial, A., Watson, C., Johns, A., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M., Samra, J., Gill, A., Chin, V., Sebastian, L., Sjoquist, K., Yip, S., Pavlakis, N., Grimison, P., Simes, R., et al (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 21(9), 2029-2037. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Karapetis, C., Cheong, K., Yip, D., Strickland, A., Steer, C., Marx, G., Yip, S., Chrystal, K., Harper, P. (2010). A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology, 6(4), 289-305. [More Information]

Conferences

  • Yip, S. (2011). Translational research and personalised medicine. The Australian New Zealand Gynaecological Oncology Group (ANZGOG) ASM.

2016

  • Pavlakis, N., Sjoquist, K., Martin, A., Tsobanis, E., Yip, S., Kang, Y., Bang, Y., Alcindor, T., O'Callaghan, C., Burnell, M., Wong, K., Simes, R., et al (2016). Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial. Journal of Clinical Oncology, 34(23), 2728-2735. [More Information]

2015

  • Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
  • Chantrill, L., Nagrial, A., Watson, C., Johns, A., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M., Samra, J., Gill, A., Chin, V., Sebastian, L., Sjoquist, K., Yip, S., Pavlakis, N., Grimison, P., Simes, R., et al (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 21(9), 2029-2037. [More Information]

2011

  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Yip, S. (2011). Translational research and personalised medicine. The Australian New Zealand Gynaecological Oncology Group (ANZGOG) ASM.

2010

  • Karapetis, C., Cheong, K., Yip, D., Strickland, A., Steer, C., Marx, G., Yip, S., Chrystal, K., Harper, P. (2010). A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology, 6(4), 289-305. [More Information]

To update your profile click here. For support on your academic profile contact .